, diseases such as diabetes or HIV-1 infection 3 , or any combination of these factors.
Clinical cases of neuropathic pain are relatively insensitive to morphine or other opioid drugs, which are normally the most powerful painkillers available 4 . This necessitates the development of new drug strategies for treating painful neuropathies. Examples of newer, non-opioid drugs with novel mechanisms of action include gabapentin, pregabalin and ziconotide 5, 6 . The effectiveness of these treatments is largely based on the premise that damage to the peripheral nervous system (PNS) produces chronic changes in neuronal excitability within the dorsal root ganglia (DRG) and/or the spinal cord dorsal horn [7] [8] [9] [10] [11] . This neuropathic neuronal activity can present as spontaneous discharge and ectopic activity in sensory neurons that are directly compromised by injury and adjacent uninjured sensory neurons [12] [13] [14] [15] [16] and/or heightened synaptic transmission in the somatosensory neurons in the spinal cord dorsal horn 17 . It is likely that these drugs act by blocking voltage-dependent Ca 2+ channels and neurotransmitter release from affected neurons [18] [19] [20] . Nevertheless, these new agents are only a start and more effective drugs or therapies still need to be developed. Indeed, ziconotide, for example, is a peptide that is based on the structure of a cone snail toxin that blocks Ca 2+ channels 21 . Although it is effective, ziconotide can only be administered by intrathecal injection, which limits its application 22 . The development of new drugs for neuropathic pain necessitates an in-depth understanding of the cellular and molecular mechanisms involved in the development of the chronic pain that follows peripheral nerve injury. Despite the discovery of numerous molecules thought to be essential for the development and maintenance of neuropathic pain, few therapies based on these molecules have been successful. One reason for this could be a lack of appreciation of the neuroinflammatory response that frequently accompanies peripheral nerve injury and the resultant neuropathic pain Abstract | Chronic (neuropathic) pain is one of the most widespread and intractable of human complaints, as well as being one of the most difficult syndromes to treat successfully with drugs or surgery. The development of new therapeutic approaches to the treatment of painful neuropathies requires a better understanding of the mechanisms that underlie the development of these chronic pain syndromes. It is clear that inflammatory responses often accompany the development of neuropathic pain, and here we discuss the idea that chemokines might be key to integrating the development of pain and inflammation and could furnish new leads in the search for effective analgesic agents for the treatment of painful neuropathies. 23 , as the cascade of inflammatory events that accompanies most nervous tissue injury is a major contributor to the establishment and maintenance of neuropathic pain.
CHEMOKINES: INTEGRATORS OF PAIN AND INFLAMMATION

Neuroinflammation
Damage to the PNS (FIG. 1) and the surrounding nonnervous tissue elicits an inflammatory response that includes increased blood supply at the site of injury, changes in capillary permeability and migration of peripheral blood leukocytes out of post-capillary venules into the surrounding tissue 24 . The migration of different types of leukocytes to the compromised area facilitates microbicidal activity, immunological defence mechanisms and wound healing, and is invariably accompanied by pain and tenderness 23 . This complex inflammatory response is orchestrated by the action of groups of cytokines and other molecules, including eicosanoids, free radicals and transcription factors such as those in the nuclear factor-κB (NF-κB) family. Of particular interest are the chemokines (chemotactic cytokines) 25 TABLES 1,2. These small, secreted proteins are vital for organizing the directed trafficking of leukocytes under normal conditions and in response to tissue damage, when they target cells to sites of inflammation. In keeping with these observations, chemo kines have been shown to be intimately involved in the inflammatory responses that accompany damage to the PNS [26] [27] [28] [29] . The inflammatory response is further amplified by the activation of glial cells of the PNS and central nervous system (CNS) (for example, satellite and Schwann cells (PNS); astrocytes and microglia (CNS)).
Activation in the PNS comprises increased expression of GLIAL FIBRILLARY ACIDIC PROTEIN, whereas CNS glia undergo a hypertrophic change in cell morphology that is accompanied by upregulation of the synthesis of many types of molecules, including numerous chemokines and proinflammatory cytokines 23, 30, 31 . Cytokines such as tumour-necrosis factor-α (TNFα) and interleukin-1β (IL-1β) are rapidly produced as part of the neuroinflammatory cascade 32, 33 and exert direct biological effects on neurons through specific cell-surface receptors. These receptors are normally present on many primary afferent neurons and their axon projections 34, 35 , and expression of the receptor can be upregulated after nerve lesion 34, 36 .
Neuroinflammation and pain states
During the course of a nerve injury-or disease-induced inflammatory response of the nervous system, proinflammatory mediators act synergistically to induce and maintain the development of pain and hyperalgesia by changing axonal properties of both injured and uninjured neurons 37 . The proinflammatory cytokines TNFα and IL-1β have proanalgesic effects that serve to either activate (generation of an action potential within the neuronal membrane) or sensitize NOCICEP TORS without directly initiating an action potential but reducing the threshold required for depolarization 23, 38 . The first indications that proinflammatory cytokines could produce hyperalgesic effects came from studies using intraplantar injections of TNFα and IL-1β 32, 33 . A recent study by Schafers 39 and colleagues shows that TNFα directly affects both injured and uninjured DRG neurons and that these changes in neuronal properties are likely to be associated with p38 mitogen-activated protein kinase 40 and/or protein kinase A 41 . The influence of proinflammatory cytokines such as TNFα and IL-1β on nociception is not limited to acute inflammatory pain states, as signalling of neuronal TNFα and IL-1β receptors via the pleiotropic transcription factor NF-κB probably results in the production of many chemokines, including monocyte chemoattractant protein-1 (MCP1), by neuronal and non-neuronal cells that are associated with peripheral nerve injury [42] [43] [44] . Subsequent experiments showed that cytokine antagonists, inhibitors of glial cell activation or chemokine receptor gene deletion (see below) reduce nociceptive behaviour in rodents, indicating that cytokine and/or chemokine synthesis is an important step in the development of neuropathic pain [45] [46] [47] [48] . In summary, nerve injury, trauma and/or infection produces a cascade of cellular events in the PNS. These events include the activation of various cell types in peripheral nerves/DRG, a neuroinflammatory response with the release of chemical mediators, including many proinflammatory cytokines and chemokines, and ultimately increased neuronal excitability. Together, these events are likely to contribute to allodynia, hyperalgesia and the other phenomena that make up the neuropathic pain syndrome 23 . How are all these events coordinated? Several chemokines have recently been shown to excite primary sensory neurons 44, 49, 50 , which indicates that chemokine receptors are also expressed by sensory nociceptors 44, 50, 51 -properties that make them ideal integrators of many aspects of the responses described. Here, we review this information and suggest how the chemokine system could afford new leads in the search for analgesic drugs.
What are chemokines?
More than 50 different chemokines have been identified in higher vertebrates 52 . Chemokines are small proteins consisting of about 100 amino acids, and fall into four subfamilies based on structural motifs 52, 53 TABLES 1, 2. Most chemokines are members of the CC (CC motif, β-chemokine) and CXC (α-hemokine) subfamilies. Chemokines belonging to the CC subfamily contain two contiguous cysteines near the amino terminus of the molecule, whereas a single amino acid separates the two cysteines in members of the CXC subfamily. Chemokines in the CX3C (δ-chemo kine) subfamily have three amino acids between the two cysteines. The fourth subfamily comprises chemokines with a single cysteine -designated the C (γ-chemokine) subfamily. Every chemokine has two names -a name that reflects a particular aspect of its biology (for example, stromal cell-derived factor-1: SDF1), and a systematic name that reflects its structure (for example, SDF1 is also called CXCL12). Each subfamily of chemokines acts on a group of related G-protein-coupled receptors (GPCRs). It has been observed in in vitro studies that a single chemokine can activate more than one receptor, and, conversely, a single cloned receptor can frequently be activated by more than one chemokine -although it is probable that their selectivity is actually higher in vivo 54 . However, there are chemokines that activate only one receptor -for example, SDF1 solely activates the CXCR4 receptor.
Chemokines and the nervous system. In addition to immune and inflammatory functions, chemokines mediate several other processes throughout the body, 
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Classification system of the various chemokines, including the receptors that they activate. Chemokines are classified based on their structure, with most falling into the CXC-and CC-chemokine classes. Most chemokines have a common name and a systematic name.
Chemokines activate a family of receptors known as the G-protein-coupled receptors, and most are able to activate more than one. BLC, B lymphocyte chemoattractant; BRAK, breast-and kidney-expressed chemokine; CCLx, CC ligand; CCRx, CC receptor; ELC, Epstein-Barr virusinduced molecule 1 ligand chemokine; ENA, epithelial neutrophil-activating protein; GCP, granulocyte chemotactic protein; GRO, growth-related oncogene; HCC, haemofiltrate CC chemokine; IL, interleukin; IP, interferon-γ-inducible protein; ITAC, interferon-γ-inducible T cell α chemoattractant; LARC, liver and activation-regulated chemokine; MCP, monocyte chemoattractant protein; MDC, macrophage-derived chemokine; Mig, monokine induced by interferon-γ; MIP, macrophage inflammatory protein; MPIF, myeloid progenitor inhibitory factor; NAP, neutrophil-activating peptide; PARC, pulmonary and activation-regulated chemokine; PF4, platelet factor 4; RANTES, regulated upon activation, normal T-cell expressed and secreted; SDF, stromal cell-derived factor; SLC, secondary lymphoid tissue chemokine; SRPSOX, scavenger receptor that binds phosphatidylserine and oxidized lipoprotein; TARC, thymus and activationregulated chemokine; TECK, thymus-expressed chemokine.
including the development and maturation of leukocytes, angiogenesis, metastasis, wound healing and allograft rejection 52 . Chemokines are also abundantly expressed by neurons, glia and neural progenitor cells, the major cell types of the nervous system 55 . Indeed, all these cells can elaborate the synthesis of chemokines, particularly under conditions of brain injury 55 . Combined with the normal and/or pathological nervous system expression of chemokine receptors, these chemokines potentially initiate a cascade of events leading to neuroinflammation 23 . These neuroinflammatory responses can occur in both the CNS and the PNS and are clearly important in the establishment of neuropathic pain.
The chemokines generated in association with neuroinflammation are crucial for the migration of leukocytes into inflamed neural tissue, just as in other parts of the body 25 . However, the functions of chemokines in the nervous system extend far beyond their role as mediators of inflammation. For example, CXCR4-receptor-knockout mice show abnormalities in the development of several neuronal structures, such as the dentate gyrus of the hippocampus, the cerebellum and the DRG 56, 57 . These phenotypes result from deficits in the chemokine-mediated migration of neural stem cells. Chemokines could also be involved in the regulation of neuronal excitability, neurotransmitter release and neuronal survival 53 . These possibilities are supported by the extensive expression patterns of some chemokines and their receptors throughout the developed brain [58] [59] [60] [61] [62] [63] , and by the reported actions of chemokines on phenomena such as neuronal excitability and transmitter release in both the CNS 49, [64] [65] [66] and PNS 43, 44, 50 . Interestingly, although many chemokines are not normally expressed at high levels in the brain, their synthesis can be dramatically upregulated in association with neuroinflammatory responses 55 . Primary afferent sensory neurons present in the DRG express many types of chemokine receptors 50, 51, [67] [68] [69] , and activation of these receptors can produce strong neuronal excitation and pain 50 (FIG. 2) . This raises the interesting possibility that the same molecules that orchestrate the inflammatory response might also act directly on sensory neurons to produce pain 44 .
Chemokines and neuropathic pain. The initial observations on the effects of chemokines on sensory neurons were carried out in cell culture 49, 50 . More recent evidence from a series of in vivo experiments in the experimental pain model known as chronic compression of the lumbar DRG (CCD) suggests that the unusual expression of the chemokine MCP1 and its cognate receptor could be central to the maintenance of neuropathic pain behaviour: CCD produces a neuroinflammatory response 70 and cutaneous hyperalgesia [71] [72] [73] . In this rodent model of spinal stenosis, the chemokine receptor CCR2 is upregulated in both the damaged and adjacent undamaged DRG 44 (FIG. 3) . The chemokines that activate CCR2 receptors are members of the MCP family. Intriguingly, when the electrophysiological effects of MCP1 signalling were tested in DRG neurons using intact ganglia in vitro, MCP1 had no effect in naive control animals, but was a powerful excitant of sensory neurons previously exposed to CCD (R. LaMotte and J. Sun) 44 . Interestingly, small-and medium-diameter DRG neurons subjected to CCD showed MCP1 immunoreactivity, whereas infiltrating macrophages and associated glial cells did not 44 . Similar findings of neuronal expression of MCP1 are evident in the rat sciatic nerve transection 43 . However, sciatic nerve transection is also accompanied by non-neuronal sources of MCP1 present in the distal nerve injury site. This non-neuronal MCP1 synthesis is probably the result of an inflammatory cytokine cascade that involves the synthesis of TNFα, IL-1β, IL-6 and leukaemia inhibitory factor (LIF) 42, 74, 75 . As such, the production of MCP1 after PNS injury could serve several functions. One such function could be to attract leukocytes that express CCR2 
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Chemokines activate a family of receptors known as the G-protein-coupled receptors, and most are able to activate more than one. BLC, B lymphocyte chemoattractant; BRAK, breast-and kidney-expressed chemokine; CCLx, CC ligand; CCRx, CC receptor; ELC, Epstein-Barr virusinduced molecule 1 ligand chemokine; ENA, epithelial neutrophil-activating protein; GCP, granulocyte chemotactic protein; GRO, growth-related oncogene; HCC, haemofiltrate CC chemokine; IL, interleukin; IP, interferon-γ-inducible protein; ITAC, interferon-γ-inducible T cell α chemoattractant; LARC, liver and activation-regulated chemokine; MCP, monocyte chemoattractant protein; MDC, macrophage-derived chemokine; Mig, monokine induced by interferon-γ; MIP, macrophage inflammatory protein; MPIF, myeloid progenitor inhibitory factor; NAP, neutrophil-activating peptide; PARC, pulmonary and activation-regulated chemokine; PF4, platelet factor 4; RANTES, regulated upon activation, normal T-cell expressed and secreted; SDF, stromal cell-derived factor; SLC, secondary lymphoid tissue chemokine; SRPSOX, scavenger receptor that binds phosphatidylserine and oxidized lipoprotein; TARC, thymus and activationregulated chemokine; TECK, thymus-expressed chemokine. into peripheral nerve and/or ganglia injury sites. In addition, if MCP1 is released by neurons, it could either reduce the membrane threshold necessary for neuronal excitation or directly excite CCR2-expressing nociceptive neurons by autocrine or paracrine processes. In turn, a reduced membrane threshold could facilitate spontaneous action potentials in nonnociceptive neurons. One prediction from this model would be that inhibition of the cognate MCP1 receptor, CCR2, would ameliorate the development of pain in animal neuropathic pain models. Results from a recently published study using CCR2-knockout mice support this prediction -although CCR2-knockout mice appeared normal in most respects, they showed reductions in both the recruitment of leukocytes to damaged peripheral nerves and the development of neuropathic pain symptoms 48 . The status of chemokine synthesis by neurons is interesting. Although it seems clear that MCP1 can be synthesized by sensory neurons, the circumstances that dictate its release are not yet understood. It is possible that it is packaged and released like a neurotransmitter, or it could be constitutively secreted. However, this is still to be determined. As data from both in vitro and in vivo studies suggest that numerous types of chemokine receptors could potentially be expressed by DRG neurons 44, 50, 51, 67, 76 , it is plausible that other receptors, in addition to CCR2, could have a role in mediating interactions between neuroinflammation and pain in different circumstances. In the special case of HIV-1-associated neuropathic pain, the role of the CXCR4 and CCR5 receptors could be of particular importance (discussed below). In response to focal segmental demyelination produced by local lysophosphatidylcholine application, which is a model of Guillain-Barré syndrome, CCR5 and CXCR3 receptors are upregulated in the associated lumbar ganglia, in addition to a neuronal upregulation in CCR2 (S.K. Bhangoo, F.A. White and R.J. Miller, unpublished observations). Ligands for these receptors, such as RANTES (regulated on activation, normal T cell expressed and secreted) and interferon-inducible protein 10 (IP10), are also commonly upregulated during neuroinflammatory responses 77, 78 and so could also exert direct effects on nociceptive and non-nociceptive neuron excitability. Indeed, various chemokines excite cultured nociceptors and produce mechanical allodynia when injected into the inflamed rat paw 50, 51, 67 . In addition to such direct effects on nociceptors, there are other scenarios in which chemokines could be important in the context of neuropathic pain. One of these concerns the unusual chemokine fractalkine (CX3CL1) and its receptor CX3CR1. Normally, fractalkine is expressed by neurons, including sensory neurons in the DRG 68, 79 , and its receptor is expressed by various cell types, including astrocytes and microglia 79, 80 . Fractalkine, in its membrane-bound conformation, can activate its receptor. However, in response to neuronal activity, fractalkine can be cleaved by matrix metalloproteinases, and soluble fractalkine can act at a distance from its source [81] [82] [83] . These interactions have been explored in the context of neuropathic pain 68, 79, 84 . According to one hypothesis, activation of fractalkine release, perhaps in response to an inflammatory cytokine such as TNFα, might induce local microglia migration and activation, as well as enhance aspects of the neuropathic response. Indeed, intrathecal administration of fractalkine in rats produces allodynia and injection of a CX3CR1-blocking antibody prevents both the development and maintenance of neuropathic pain, indicating that fractalkine signalling could be involved in the chronic nature of the neuropathic pain response 79 . In summary, there are several points at which chemo kines could potentially be important for the development and maintenance of painful neuro pathies. Chemokines can be synthesized by nociceptive neurons and by other cells in response to injury. These chemokines can then activate receptors on macrophages and microglia, resulting in their migration and enhancing their activation. Importantly, the chemokines RANTES, SDF1α, MCP1 and fractalkine 44, 50, 79 can act directly on nociceptive neurons to produce excitation and, in some cases, pain 50, 79 . Taking all this evidence into consideration, drugs that inhibit chemokine receptor function would be predicted to be useful in treating painful neuropathies.
HIV-1-associated neuropathies
Chemokines and their receptors are of particular importance in HIV-1 infection 3 , as the chemokine receptors CCR5 and CXCR4, together with the CD4 molecule, represent the major cellular receptors for viral transfection of leukocytes, such as macrophages and microglia. Infected macrophages and/or microglial cells contribute to the neuroinflammatory response by producing chemokines 85, 86 . Although HIV-1 does not infect neurons directly, the viral coat protein gp120 is shed by the virus (depending on the viral strain 87 ) and can bind to both neuronal and non-neuronal CCR5 and CXCR4, facilitating receptor signalling in both the PNS and CNS [87] [88] [89] . This neuronal chemokine/receptor signalling probably contributes to various neuropathologies, including severe painful neuropathies 90 . The aetiology of painful neuropathies associated with HIV-1 remains elusive, but up to 41% of patients infected with HIV-1 develop severe painful neuropathies, even before they develop AIDS [91] [92] [93] . The viral coat protein gp120 can also act as an agonist or antagonist of chemokine action, depending on the circumstances 94 (FIGS 2,4) 50 , and prolonged treatment of DRG neurons with gp120 produces apoptosis 95 . However, as studies on the correlates of HIV-1 neuropathy have established that the virus does not infect DRG neurons, the resulting effects on sensory neuron function could be indirect 89, 96 . The situation is therefore similar to the effects of HIV-1 on the CNS 97,98 -viral infection results in deficits in cognition and motor function, although HIV-1 only productively infects macrophages and microglia with high viral loads 3 . The development of neuropathic pain cannot be completely attributed to HIV-1 infection of cells associated with the nervous system, as similar painful peripheral neuropathies have been associated with the use of the highly active antiretroviral treatment (HAART) drugs used to combat HIV-1 infection, such as zidovudine (AZT), zalcitabine (ddC), didanosine (ddI) and stavudine (d4t) 2 . The combination of HIV-1 and HAART drugs could be synergistic for the development of painful neuropathies 3, 99 . The most common painful peripheral neuropathy -distal symmetric polyneuropathy (DSP) -occurs in late-stage HIV/AIDS. DSP typically presents during advanced immunosuppression, with symptoms ranging from distal symmetric numbness to tingling and burning sensations 100 . With the onset of HAART therapy, several other neuropathologies have been noted, including inflammatory demyelinating polyneuropathy (IDP) and progressive polyradiculopathy. IDP has an early to late onset and is marked by progressive weakness and PARATHESIAS. Progressive polyradiculopathy is more likely to occur with advanced immunosuppression, and could be due to an opportunistic cytomegalovirus infection: symptoms include weakness in the lower extremities and parathesias.
The mechanism of HAART neurotoxicity seems to be related to a metabolic toxicity [101] [102] [103] , although second messenger signalling pathways, such as changes in Ca 2+ buffering at the distal axon peripheral termination 104 , have also been implicated [105] [106] [107] . Reported neuropathological changes associated with the administration of nucleoside reverse transcriptase inhibitors (NRTIs) include shrunken axons, axon splitting, large periaxonal spaces, macrophage infiltration and persistent MYELINOPATHY (that is, myelin balls, ovoids and varicosities) 108 . There are also reports of the loss of small, unmyelinated nerve fibre, which is sometimes accompanied by large myelinated fibre loss in advanced cases 100, 109, 110 . Infiltration of both the DRG and peripheral nerves by macrophages has been noted in humans 111 and rodents 108 treated with NRTIs. Notably, the amount of MCP1 in cerebral spinal fluid is substantially greater in HIV-1 patients receiving HAART treatment than it is in HIV-1-positive control patients 85, 86 . Chemokines secreted by macrophages, dendritic cells and microglia activated in association with HIV-1 infection are clearly important in the recruitment of other leukocytes to the DRG and peripheral nerves [112] [113] [114] . These chemokines might also produce neuropathic pain by acting directly on receptors expressed by both nociceptive and non-nociceptive neurons. Together with the HAART-induced neurotoxicity, activation of neuronal chemokine receptors could synergistically augment painful neuropathies in several ways, ranging from the overall consequences of neuroinflammation to the viral-induced activation of chemokine receptor-induced events in neurons and glia. The viral coat protein gp120 can bind to the chemokine (CC motif) receptors CCR5 and CXCR4 and can also act as an agonist or antagonist of chemokine action, depending on the circumstances 94 . For example, gp120 can directly excite cultured dorsal root ganglia (DRG) neurons in a similar mode to chemokines and direct injection of gp120 into the rat paw produces allodynia (FIG. 2) 
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. In addition, prolonged treatment of DRG neurons with gp120 produces apoptosis 95 . Therefore, gp120 might induce some features of HIV-1 neuropathy through direct effects on chemokine receptors that are expressed by DRG neurons. It has also been suggested that gp120 could produce effects through the activation of CXCR4 receptors expressed by Schwann cells 89, 145 . According to one hypothesis, activation of these receptors by gp120 causes Schwann cells to secrete the chemokine RANTES (regulated on activation, normal T cell expressed and secreted). RANTES can then activate CCR5 receptors expressed by DRG neurons, which could produce pain through direct excitation 89 . RANTES can also stimulate tumour-necrosis factor-α (TNFα) production by DRG neurons 89 . TNFα might then act in a cell-autonomous manner to produce excitation and pain or neuronal apoptosis
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. Interestingly, TNFα also suppresses the expression of CXCR4 receptors by Schwann cells and is toxic to these cells. So, it seems that HIV-1 could trigger painful neuropathies in several ways, ranging from the overall consequences of neuroinflammation to the viral-induced activation of chemokine-receptor-induced events in neurons and glia. TNFR, tumour-necrosis factor receptor. 
Chemokine receptor signalling and pain
Which signalling pathways are engaged by chemokines in the context of neuropathic pain and might these also be potential therapeutic targets (FIG. 5) . The normal role of TRPV1 is to respond to heat in the pain-producing range ('noxious heat') and also to protons that are present in the neuro inflammatory milieu. TRPV1 is also the receptor for capsaicin, the irritant pain-producing substance that is synthesized by hot peppers. Normally, TRPV1 channels are tonically blocked by the phospholipid phosphatidylinositol 4,5-bisphosphate (PIP 2 ), which is situated on the inner leaflet of the cell membrane 121 . After activation of bradykinin receptors, phospholipase C is activated, which hydrolyses PIP 2 into inositol triphosphate and diacylglycerol (DAG) and induces Ca 2+ mobilization 121 . However, the hydrolysis of PIP 2 also leads to the unblocking of TRPV1, allowing Na + entry down its electrochemical gradient and depolarization of the neuron 121 . A recent publication has reported that activation of CCR1 receptors that are expressed by DRG neurons produces transactivation of the TRPV1 receptor, which is reported to be an important mechanism in the ability of this chemokine to produce pain 67 . Furthermore, many chemokines stimulate phospholipase C and effect Ca 2+ mobilization in sensory neurons 49 . Therefore, this signalling pathway might be a key element in other instances of chemokine-induced sensory neuron excitation and resulting pain (FIG. 5) .
The consequences of chemokine receptor activation have other effects on DRG function that might amplify nociceptive signalling. For example, the opiate system is a major signalling system that serves to decrease the flow of painful information from the DRG into the spinal cord. Opiate receptors are also expressed by nociceptors and their activation has powerful antinociceptive effects, as typified by the universal use of morphine as an analgesic. Why then are opiates not particularly effective in the treatment of neuropathic pain? In cells that co-express chemokine and opiate receptors, activation of chemokine receptors leads to cross desensitization of opiate receptors [122] [123] [124] . This could be the result of transphosphorylation of opiate receptors and/or heterodimerization of chemokine and opiate receptors [125] [126] [127] . Desensitization is also observed in the opposite direction -that is, downregulation of chemokine receptor function after activation of opiate receptors 122, 128 . The interacting roles of opiates and chemokines in the regulation of pain are clearly complex. For example, during inflammation, certain infiltrating leukocytes secrete opioid peptides that act on nociceptors to ameliorate painful effects [129] [130] [131] . As chemokines have an important role in attracting leukocytes into the nerves and ganglia, they encourage migration of cells that secrete antinociceptive opioid peptides, and also serve to desensitize opiate receptor function in the DRG through a process of cross desensitization. The overall consequences of these apparently contradictory effects for pain perception presumably depend on the exact context. . MCP1 can also attract leukocytes into the ganglia. Some of these can secrete endorphins [129] [130] [131] that activate opiate receptors and reduce neuronal excitability. In addition, activation of CCR2 receptors by MCP1 can cross-desensitize opiate receptor function [122] [123] [124] . NATURE REVIEWS | DRUG DISCOVERY VOLUME 4 | OCTOBER 2005 | 841
Chemokine receptors as therapeutic targets
The data discussed here indicate that chemokines and their receptors have a previously unappreciated role in the genesis and maintenance of neuropathic pain. Therefore, agents that block chemokine receptors could constitute a new class of drugs for the treatment of this condition. Indeed, targeting chemokine receptors might have some particular advantages. As we have discussed above, chemokines such as MCP1 are involved in organizing inflammatory reactions and in directly producing pain by activating CCR2 receptors that are expressed by the DRG. So, inhibiting these receptors could potentially have two beneficial effects -a reduction in inflammatory responses and an analgesic effect. The results of studies using CCR2-knockout animals support this assertion. However, as yet, there is no real proof-of-principle study using a small-molecule CCR2 antagonist, although an inhibitor of the CCR2 receptor has been reported that seems to have anti-pain activity in the neuropathic pain model of partial sciatic nerve ligation, which would support the proposed benefits of targeting these receptors 132 . These results suggest that chemokine receptor antagonists could have antinociceptive/analgesic properties of the type discussed here and should be considered as a potentially new therapeutic approach to intractable neuropathic pain. However, there is clearly a great deal to be done to test this hypothesis properly. Producing small-molecule inhibitors for chemokine receptors has been quite an active field of medicinal chemistry, particularly because antagonists of the CCR5 and CXCR4 receptors inhibit viral replication of HIV-1 and several archetypal drugs of this type have been produced 133 . The most thoroughly investigated of these is the bicyclam AMD3100, an agent that is efficacious in blocking CXCR4 receptors and inhibiting the infection of cells by CXCR4-specific strains of HIV-1 REF. 134. Other agents, such as TAK-779, that block CCR5 receptors 133, 135 have been synthesized. In addition, some agents have been produced that block other chemokine receptors, such as CCR1, CXCR1 and CXCR2, in the search for new anti-inflammatory leads 136, 137 , as well as for therapeutic treatments for rheumatoid arthritis, multiple myeloma, graft rejection and numerous other indications 138 . Although several of these agents are currently in advanced clinical trials and seem to be generally safe, the involvement of chemokine receptors in the development of neuropathic pain is a relatively new concept, and so none of these agents has been tested for this indication. However, because several good models for painful neuropathies now exist, for example, for neuropathies associated with cancer 139 , drug toxicity 89, 140 , diabetes 141 , spinal cord trauma 142 and demyelinating disease 143, 144 , it should be possible to obtain preclinical indications as to their usefulness in this regard. The realization that chemokine receptors have such a key role in integrating neuropathic pain and inflammation underlines that this will be a fruitful approach to identifying new therapies for these extremely widespread and intractable syndromes.
